Viatris Inc. has announced positive top-line results from its Phase 3 LYNX-2 trial evaluating MR-142, a phentolamine ophthalmic solution 0.75%, for treating significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision. The trial, conducted under a Special Protocol Assessment with the U.S. FDA, demonstrated that MR-142 met its primary endpoint, showing a ≥15-letter (≥3-line) improvement in mesopic low contrast distance visual acuity compared to placebo. The randomized, placebo-controlled study involved 199 patients and was conducted over a 6-week period. No evidence of tachyphylaxis was observed. The FDA has granted Fast Track designation to MR-142, potentially accelerating its development and review process. A second pivotal study, LYNX-3, is expected to commence soon, with results expected in the first half of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.